



EFW

PATENT

1505-1052

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

Vladimir BYKOV et al.

Conf. 8979

Application No. 10/505,407

Group 1711

Filed August 23, 2004

USE OF LOW MOLECULAR WEIGHT COMPOUNDS
FOR PREPARING A MEDICAMENT USEFUL IN
TREATING MUTANT P53 MEDIATED DISEASES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with Rules 1.97 and 1.98, and in fulfillment of the duty of disclosure under Rule 1.56, the accompanying document, a copy of which is attached to this statement, is made of record on the enclosed Form PTO-1449.

A concise explanation of the relevance of this item is that this reference was cited in the corresponding International Application Serial No. PCT/SE03/00206, filed February 7, 2003. A copy of the International Search Report in which it was cited was filed with the Information

Disclosure Statement filed August 23, 2004 in the present application.

Respectfully submitted, .

YOUNG & THOMPSON

A handwritten signature in cursive script that reads "Benoit Castel". The signature is written in dark ink and is positioned above a horizontal line.

Benoit Castel, Reg. No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

BC/fb

February 23, 2005

RE CITATION
ION
FEB 23 2005
MARK OFFICE

CONFIDENTIAL

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Chemical Abstract 83:186204 Antitumor chemotherapy. XIV. Cytotoxic activity of molecules possessing an ethylenic double bond substituted in α and β positions by an electron-attracting group. Dore, Jean C.; Viel, Claude (Cent. Etud. Rech. Chim. Org. Appl., Thiais, Fr.). European Journal of Medicinal Chemistry, 10(1), 47-54 (French) 1975.

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

* Abstract provided for the Examiner's convenience